Skip to main content
Erschienen in: Cancer Immunology, Immunotherapy 7/2015

01.07.2015 | Focussed Research Review

Adoptive immunotherapy of cancer utilizing genetically engineered lymphocytes

verfasst von: Hiroaki Ikeda, Hiroshi Shiku

Erschienen in: Cancer Immunology, Immunotherapy | Ausgabe 7/2015

Einloggen, um Zugang zu erhalten

Abstract

It is becoming increasingly clear that adoptive immunotherapy with genetically engineered T cells has the potential to control and even cure cancer in some patients. On the other hand, severe adverse events associated with efficacy have frequently been reported in clinical trials. Current and near-future challenges for the development of adoptive immunotherapy of cancer using genetically engineered T cells include minimization and prediction of adverse events; identification of new and effective targets, including patient-specific mutations; improvement in T cell functionality, persistence, and memory formation capacity; and utilization of allogeneic or cell line-based T cells.
Literatur
1.
Zurück zum Zitat Jenq RR, van den Brink MR (2010) Allogeneic haematopoietic stem cell transplantation: individualized stem cell and immune therapy of cancer. Nat Rev Cancer 10(3):213–221PubMedCrossRef Jenq RR, van den Brink MR (2010) Allogeneic haematopoietic stem cell transplantation: individualized stem cell and immune therapy of cancer. Nat Rev Cancer 10(3):213–221PubMedCrossRef
3.
Zurück zum Zitat Rosenberg SA, Lotze MT, Yang JC et al (1993) Prospective randomized trial of high-dose interleukin-2 alone or in conjunction with lymphokine-activated killer cells for the treatment of patients with advanced cancer. J Natl Cancer Inst 85(8):622–632PubMedCrossRef Rosenberg SA, Lotze MT, Yang JC et al (1993) Prospective randomized trial of high-dose interleukin-2 alone or in conjunction with lymphokine-activated killer cells for the treatment of patients with advanced cancer. J Natl Cancer Inst 85(8):622–632PubMedCrossRef
4.
Zurück zum Zitat Boon T, Coulie PG, van den Eynde BJ, van den Brugen PV (2006) Human T cell responses against melanoma. Annu Rev Immunol 24:175–208PubMedCrossRef Boon T, Coulie PG, van den Eynde BJ, van den Brugen PV (2006) Human T cell responses against melanoma. Annu Rev Immunol 24:175–208PubMedCrossRef
5.
Zurück zum Zitat Restifo NP, Dudley ME, Rosenberg SA (2012) Adoptive immunotherapy for cancer: harnessing the T cell response. Nat Rev Immunol 12:269–281PubMedCrossRef Restifo NP, Dudley ME, Rosenberg SA (2012) Adoptive immunotherapy for cancer: harnessing the T cell response. Nat Rev Immunol 12:269–281PubMedCrossRef
6.
Zurück zum Zitat Rosenberg SA (2011) Cell transfer immunotherapy for metastatic solid cancer-what clinicians need to know. Nat Rev Clin Oncol 8:577–585PubMedCrossRef Rosenberg SA (2011) Cell transfer immunotherapy for metastatic solid cancer-what clinicians need to know. Nat Rev Clin Oncol 8:577–585PubMedCrossRef
7.
Zurück zum Zitat Kalos M, June CH (2013) Adoptive T cell transfer for cancer immunotherapy in the era of synthetic biology. Immunity 39:49–60PubMedCrossRef Kalos M, June CH (2013) Adoptive T cell transfer for cancer immunotherapy in the era of synthetic biology. Immunity 39:49–60PubMedCrossRef
8.
Zurück zum Zitat Johnson LA, Morgan RA, Dudley ME, Cassard L, Yang JC, Hughes MS et al (2009) Gene therapy with human and mouse T-cell receptors mediates cancer regression and targets normal tissues expressing cognate antigen. Blood 114:535–546PubMedCentralPubMedCrossRef Johnson LA, Morgan RA, Dudley ME, Cassard L, Yang JC, Hughes MS et al (2009) Gene therapy with human and mouse T-cell receptors mediates cancer regression and targets normal tissues expressing cognate antigen. Blood 114:535–546PubMedCentralPubMedCrossRef
9.
Zurück zum Zitat Robbins PF, Norgan RA, Feldman SA, Yang JC, Sherry RM, Dudley ME et al (2011) Tumor regression in patients with metastatic synovial cell sarcoma and melanoma using genetically engineered lymphocytes reactive with NY-ESO-1. J Clin Oncol 29:917–924PubMedCentralPubMedCrossRef Robbins PF, Norgan RA, Feldman SA, Yang JC, Sherry RM, Dudley ME et al (2011) Tumor regression in patients with metastatic synovial cell sarcoma and melanoma using genetically engineered lymphocytes reactive with NY-ESO-1. J Clin Oncol 29:917–924PubMedCentralPubMedCrossRef
10.
Zurück zum Zitat Maude SL, Frey N, Saw PA, Aplenc R, Barrett DM, Bunin NJ et al (2014) Chimeric antigen receptor T cells for sustained remissions in leukemia. New Engl J Med 371:1507–1517PubMedCentralPubMedCrossRef Maude SL, Frey N, Saw PA, Aplenc R, Barrett DM, Bunin NJ et al (2014) Chimeric antigen receptor T cells for sustained remissions in leukemia. New Engl J Med 371:1507–1517PubMedCentralPubMedCrossRef
11.
Zurück zum Zitat Lee DW, Kochenderfer JN, Stetler-Stevenson M, Cui YK, Delbrook C, Feldman SA et al (2015) T cells expressing CD19 chimeric antigen receptors for acute lymphoblastic leukaemia in children and young adults: a phase 1 dose-escalation trial. Lancet 385(9967):517–528PubMedCrossRef Lee DW, Kochenderfer JN, Stetler-Stevenson M, Cui YK, Delbrook C, Feldman SA et al (2015) T cells expressing CD19 chimeric antigen receptors for acute lymphoblastic leukaemia in children and young adults: a phase 1 dose-escalation trial. Lancet 385(9967):517–528PubMedCrossRef
12.
Zurück zum Zitat Kochenderfer JN, Dudley ME, Kassim SH, Somerville RP, Carpenter RO, Stetler-Stevenson M et al (2015) Chemotherapy-refractory diffuse large B-cell lymphoma and indolent B-cell malignancies can be effectively treated with autologous T cells expressing an anti-CD19 chimeric antigen receptor. J Clin Oncol 33(6):540–549PubMedCrossRef Kochenderfer JN, Dudley ME, Kassim SH, Somerville RP, Carpenter RO, Stetler-Stevenson M et al (2015) Chemotherapy-refractory diffuse large B-cell lymphoma and indolent B-cell malignancies can be effectively treated with autologous T cells expressing an anti-CD19 chimeric antigen receptor. J Clin Oncol 33(6):540–549PubMedCrossRef
13.
Zurück zum Zitat Parkhurst MR, Yang JC, Langan RC, Dudley ME, Nathan DA, Feldman SA et al (2011) T cell targeting carcinoembryonic antigen can mediate regression of metastatic colorectal cancer but induce severe transient colitis. Mol Ther 19(3):620–626PubMedCentralPubMedCrossRef Parkhurst MR, Yang JC, Langan RC, Dudley ME, Nathan DA, Feldman SA et al (2011) T cell targeting carcinoembryonic antigen can mediate regression of metastatic colorectal cancer but induce severe transient colitis. Mol Ther 19(3):620–626PubMedCentralPubMedCrossRef
14.
Zurück zum Zitat Morgan RA, Chinnasamy N, Abate-Daga D, Gros A, Robbins PF, Zheng Z et al (2013) Cancer regression and neurological toxicity following anti-MAGE-A3 TCR gene therapy. J Immunother 36(2):133–151PubMedCentralPubMedCrossRef Morgan RA, Chinnasamy N, Abate-Daga D, Gros A, Robbins PF, Zheng Z et al (2013) Cancer regression and neurological toxicity following anti-MAGE-A3 TCR gene therapy. J Immunother 36(2):133–151PubMedCentralPubMedCrossRef
15.
Zurück zum Zitat Linette GP, Stadmauer EA, Maus MV, Rapoport AP, Levine BL, Emery L et al (2013) Cardiovascular toxicity and titin cross-reactivity of affinity-enhanced T cells in myeloma and melanoma. Blood 122(6):863–871PubMedCentralPubMedCrossRef Linette GP, Stadmauer EA, Maus MV, Rapoport AP, Levine BL, Emery L et al (2013) Cardiovascular toxicity and titin cross-reactivity of affinity-enhanced T cells in myeloma and melanoma. Blood 122(6):863–871PubMedCentralPubMedCrossRef
16.
Zurück zum Zitat Robbins PF, Lu YC, El-Gamil M, Li YF, Gross C, Gartner J et al (2013) Mining exomic sequencing data to identify mutated antigens recognized by adoptively transferred tumor-reactive T cells. Nat Med 19(6):747–752PubMedCentralPubMedCrossRef Robbins PF, Lu YC, El-Gamil M, Li YF, Gross C, Gartner J et al (2013) Mining exomic sequencing data to identify mutated antigens recognized by adoptively transferred tumor-reactive T cells. Nat Med 19(6):747–752PubMedCentralPubMedCrossRef
17.
Zurück zum Zitat Tran E, Turcotte S, Gros A, Robbins PF, Lu YC, Dudley ME et al (2014) Cancer immunotherapy based on mutation-specific CD4+ T cells in a patient with epithelial cancer. Science 344(6184):641–645PubMedCrossRef Tran E, Turcotte S, Gros A, Robbins PF, Lu YC, Dudley ME et al (2014) Cancer immunotherapy based on mutation-specific CD4+ T cells in a patient with epithelial cancer. Science 344(6184):641–645PubMedCrossRef
18.
Zurück zum Zitat Matsushita H, Vesely MD, Koboldt DC, Rickert CG, Uppaluri R, Magrini VJ et al (2012) Cancer exome analysis reveals a T-cell-dependent mechanism of cancer immunoediting. Nature 482(7385):400–404PubMedCrossRef Matsushita H, Vesely MD, Koboldt DC, Rickert CG, Uppaluri R, Magrini VJ et al (2012) Cancer exome analysis reveals a T-cell-dependent mechanism of cancer immunoediting. Nature 482(7385):400–404PubMedCrossRef
19.
Zurück zum Zitat Castle JC, Kreiter S, Diekmann J, Löwer M, van de Roemer N, de Graaf J et al (2012) Exploiting the mutanome for tumor vaccination. Cancer Res 72(5):1081–1091PubMedCrossRef Castle JC, Kreiter S, Diekmann J, Löwer M, van de Roemer N, de Graaf J et al (2012) Exploiting the mutanome for tumor vaccination. Cancer Res 72(5):1081–1091PubMedCrossRef
20.
Zurück zum Zitat Shirakura Y, Mizuno Y, Wang L, Imai N, Amaike C, Sato E et al (2012) T-cell receptor gene therapy targeting melanoma-associated antigen-A4 inhibits human tumor growth in non-obese diabetic/SCID/gcnull mice. Cancer Sci 103(1):17–25PubMedCrossRef Shirakura Y, Mizuno Y, Wang L, Imai N, Amaike C, Sato E et al (2012) T-cell receptor gene therapy targeting melanoma-associated antigen-A4 inhibits human tumor growth in non-obese diabetic/SCID/gcnull mice. Cancer Sci 103(1):17–25PubMedCrossRef
21.
Zurück zum Zitat Kageyama S, Ikeda H, Miyahara Y, Imai N, Ishihara M, Saito K et al (2015) Adoptive transfer of MAGE-A4 T-cell receptor gene-transduced lymphocytes in patients with recurrent esophageal cancer. Clin Cancer Res 21(10):2268–2277PubMedCrossRef Kageyama S, Ikeda H, Miyahara Y, Imai N, Ishihara M, Saito K et al (2015) Adoptive transfer of MAGE-A4 T-cell receptor gene-transduced lymphocytes in patients with recurrent esophageal cancer. Clin Cancer Res 21(10):2268–2277PubMedCrossRef
22.
Zurück zum Zitat Hosoi H, Ikeda H, Imai N, Amaike C, Wang L, Orito Y et al (2014) Stimulation through very late antigen-4 and -5 improves the multifunctionality and memory formation of CD8+ T cells. Eur J Immunol 44:1747–1758PubMedCrossRef Hosoi H, Ikeda H, Imai N, Amaike C, Wang L, Orito Y et al (2014) Stimulation through very late antigen-4 and -5 improves the multifunctionality and memory formation of CD8+ T cells. Eur J Immunol 44:1747–1758PubMedCrossRef
23.
Zurück zum Zitat Bendle GM, Linnemann C, Hooijkaas AI, Bies L, de Witte MA, Jorritsma A et al (2010) Lethal graft-versus-host disease in mouse models of T cell receptor gene therapy. Nat Med 16(5):565–570PubMedCrossRef Bendle GM, Linnemann C, Hooijkaas AI, Bies L, de Witte MA, Jorritsma A et al (2010) Lethal graft-versus-host disease in mouse models of T cell receptor gene therapy. Nat Med 16(5):565–570PubMedCrossRef
24.
Zurück zum Zitat Okamoto S, Mineno J, Ikeda H, Fujiwara H, Yasukawa M, Shiku H et al (2009) Improved expression and reactivity of transduced tumor-specific TCRs in human lymphocytes by silencing of endogenous TCR. Cancer Res 69(23):9003–9011PubMedCrossRef Okamoto S, Mineno J, Ikeda H, Fujiwara H, Yasukawa M, Shiku H et al (2009) Improved expression and reactivity of transduced tumor-specific TCRs in human lymphocytes by silencing of endogenous TCR. Cancer Res 69(23):9003–9011PubMedCrossRef
25.
Zurück zum Zitat Restifo NP, Dudley ME, Rosenberg SA (2012) Adoptive immunotherapy for cancer: harnessing the T cell response. Nat Rev Immunol 12(4):269–281PubMedCrossRef Restifo NP, Dudley ME, Rosenberg SA (2012) Adoptive immunotherapy for cancer: harnessing the T cell response. Nat Rev Immunol 12(4):269–281PubMedCrossRef
Metadaten
Titel
Adoptive immunotherapy of cancer utilizing genetically engineered lymphocytes
verfasst von
Hiroaki Ikeda
Hiroshi Shiku
Publikationsdatum
01.07.2015
Verlag
Springer Berlin Heidelberg
Erschienen in
Cancer Immunology, Immunotherapy / Ausgabe 7/2015
Print ISSN: 0340-7004
Elektronische ISSN: 1432-0851
DOI
https://doi.org/10.1007/s00262-015-1718-0

Weitere Artikel der Ausgabe 7/2015

Cancer Immunology, Immunotherapy 7/2015 Zur Ausgabe

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.